170 related articles for article (PubMed ID: 23949582)
1. The cytogenetic action of ifosfamide, mesna, and their combination on peripheral rabbit lymphocytes: an in vivo/in vitro cytogenetic study.
Bogiatzi S; Pagonopoulou O; Simopoulou M; Kareli D; Kouskoukis A; Koutka Z; Ipsilantis P; Lialiaris T
Cytotechnology; 2014 Oct; 66(5):753-60. PubMed ID: 23949582
[TBL] [Abstract][Full Text] [Related]
2. Comparision of uroprotective activity of reduced glutathione with mesna in ifosfamide induced hemorrhagic cystitis in rats.
Ali SA; Danda SK; Basha SA; Rasheed A; Ahmed O; Ahmed MM
Indian J Pharmacol; 2014; 46(1):105-8. PubMed ID: 24550594
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.
Saito Y; Kumamoto T; Makino Y; Tamai I; Ogawa C; Terakado H
Jpn J Clin Oncol; 2016 Sep; 46(9):856-61. PubMed ID: 27380806
[TBL] [Abstract][Full Text] [Related]
4. [8] and [10]-Gingerol reduces urothelial damage in ifosfamide-induced hemorrhagic cystitis via JAK/STAT/FOXO signaling pathway via IL-10.
Ferreira FCS; Clementino M; Rodrigues FAP; Veras HN; Martins DS; Queiroga ML; Lima MA; Silva DO; de Freitas TM; Ribeiro SA; Mota MRL; da Silva JA; Lima AAM; Havt A
Naunyn Schmiedebergs Arch Pharmacol; 2023 Aug; 396(8):1773-1786. PubMed ID: 36843129
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.
Patzer L; Hernando N; Ziegler U; Beck-Schimmer B; Biber J; Murer H
Kidney Int; 2006 Nov; 70(10):1725-34. PubMed ID: 17003823
[TBL] [Abstract][Full Text] [Related]
6. Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide.
Dornelas-Filho AF; Pereira VBM; Wong DVT; Nobre LMS; Melo AT; Silva CMS; Wanderley CWS; Nour ML; Araújo LCNC; Silva RO; Pinto FMM; Bingana RD; Souza MHLP; Alencar NMN; Silva PGB; Alves APNN; Almeida PRC; Cunha FQ; Lima-Júnior RCP
Int Immunopharmacol; 2018 Sep; 62():96-108. PubMed ID: 29990699
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO).
Frustaci S; Foladore S; De Pascale A; Freschi A; Lo Re G; Sorio R; Errante D; Monfardini S
Ann Oncol; 1992 Apr; 3 Suppl 2():S115-8. PubMed ID: 1622852
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of cytogenetic damage by 2-mercaptoethanesulfonate in cultured human lymphocytes exposed to cyclophosphamide and its reactive metabolites.
Wilmer JL; Erexson GL; Kligerman AD
Cancer Res; 1986 Jan; 46(1):203-10. PubMed ID: 3079586
[TBL] [Abstract][Full Text] [Related]
9. Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis.
Matz EL; Hsieh MH
Urology; 2017 Feb; 100():16-19. PubMed ID: 27566144
[TBL] [Abstract][Full Text] [Related]
10. Dosing and side-effects of ifosfamide plus mesna.
Brade WP; Herdrich K; Kachel-Fischer U; Araujo CE
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S164-86. PubMed ID: 1795007
[TBL] [Abstract][Full Text] [Related]
11. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
Sakurai M; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sano T; Suemasu K; Jett JR
Jpn J Clin Oncol; 1986 Jun; 16(2):153-6. PubMed ID: 3090314
[TBL] [Abstract][Full Text] [Related]
12. Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
Loeffler TM; Weber FW; Hausamen TU
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S125-8. PubMed ID: 1795000
[TBL] [Abstract][Full Text] [Related]
13. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1996 Jun; 23(3 Suppl 6):97-8. PubMed ID: 8677458
[TBL] [Abstract][Full Text] [Related]
14. Effects of subchronic ifosfamide-mesna treatment on testes and semen characteristics in the rabbit.
Ypsilantis P; Papaioannou N; Psalla D; Politou M; Pitiakoudis M; Simopoulos C
Reprod Toxicol; 2003; 17(6):699-708. PubMed ID: 14613822
[TBL] [Abstract][Full Text] [Related]
15. Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.
Mohrmann M; Ansorge S; Schönfeld B; Brandis M
Pediatr Nephrol; 1994 Aug; 8(4):458-65. PubMed ID: 7524598
[TBL] [Abstract][Full Text] [Related]
16. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
Brock N
Recent Results Cancer Res; 1980; 74():270-8. PubMed ID: 6777836
[TBL] [Abstract][Full Text] [Related]
17. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
Kuśnierczyk H; Konarski L; Kowalski P; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1997; 45(1):79-85. PubMed ID: 9090445
[TBL] [Abstract][Full Text] [Related]
18. In vitro/in vivo effects of Mesna on the genotoxicity and toxicity of cyclophosphamide--a study aimed at clarifying the mechanism of Mesna's anticarcinogenic activity.
Pool BL; Bos RP; Niemeyer U; Theuws JL; Schmähl D
Toxicol Lett; 1988 Apr; 41(1):49-56. PubMed ID: 3128896
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine's Cytogenetic Effect on T Lymphocytes in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: In Vitro Study.
Demirtzoglou G; Chrysoglou SI; Katopodi T; Dimitroulas T; Iakovidou-Kritsi Z; Garyfallos A; Lambropoulos A
Cureus; 2023 Apr; 15(4):e37683. PubMed ID: 37206523
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
